Who has invested in Evozyne?

Fidelity Investments, Orbimed, NVentures, Paragon Biosciences LLC, Valor Equity Partners are named among the investors backing Evozyne.

Evozyne Funding: $144M Raised, Series B (2023)

Evozyne funding overview

Evozyne is based in Chicago. Evozyne has raised $144M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in September 2023. The round record for Evozyne runs through 2023; nothing later has been disclosed. Investors on record include Fidelity Investments, Orbimed, NVentures, Paragon Biosciences LLC, Valor Equity Partners. 5 distinct backers are named across the disclosed rounds.

Evozyne at a glance

Total raised: $144M
Latest round: Series B
Latest round date: September 2023
Headquarters: Chicago
Notable investors: Fidelity Investments, Orbimed, NVentures, Paragon Biosciences LLC, Valor Equity Partners

Frequently asked about Evozyne funding

How much has Evozyne raised?: Evozyne has raised $144M in total disclosed funding across the rounds on record.
Who has invested in Evozyne?: Fidelity Investments, Orbimed, NVentures, Paragon Biosciences LLC, Valor Equity Partners are named among the investors backing Evozyne.
What was the latest Evozyne funding round?: The most recent disclosed round is a Series B, announced in September 2023.
Where is Evozyne based?: Evozyne is based in Chicago.
When did Evozyne last raise?: The last disclosed Evozyne round closed in September 2023 at Series B.

We update the Evozyne record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Chicago and their backers are listed below.

Evozyne Funding: $144M Raised, Series B (2023)

Evozyne funding overview

Evozyne at a glance

Frequently asked about Evozyne funding

Companies related to Evozyne (36)

Browse related funding lists (7)